


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of
ELLISON, R. *et al.*

Serial No.: 09/173,531

Filed: October 15, 1998

For: **COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY
AND METASTATIC NEOPLASTIC DISEASES USING ARSENIC
COMPOUNDS**



Atty. Docket No: 077319/0225

Group Art Unit: 1616

Examiner: J. Pak

TECH CENTER 1600/2900

AUG 23 2001

RECEIVED

11/a
8-25-01

**AMENDMENT AND REQUEST FOR
RECONSIDERATION UNDER 37 CFR §1.111**

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Official Action mailed March 21, 2001, the period for response to which has been extended to expire on August 21, 2001, by virtue of the accompanying petition and fee, applicants request that the PTO amend the above-identified application, as indicated below, and reconsider this case in light of the following remarks.

IN THE CLAIMS

Please cancel claims 19 and 20 and enter the following amended versions of claims 1, 2, 3, 9, 13, 14, 16 and 18 into the record.

1. (Amended) A method of treatment of solid tumors in a human in need of such treatment, which comprises administering a therapeutically effective amount of one or more arsenic compounds to said human.

2. (Amended) A method of treatment of metastatic neoplastic disease in a human in need of such treatment, which comprises administering a therapeutically effective amount of one or more arsenic compounds to said human.

08/23/2001 BNGUYEN1 00000072 09173531

02 FC:203
03 FC:204

171.00 OP
135.00 OP

002.625872.1